Gene expression profiling reveals that the regulation of estrogen-responsive element-independent genes by 17β-estradiol-estrogen receptor β is uncoupled from the induction of phenotypic changes in cell models

Journal of Molecular Endocrinology

Volumn 40, Issue 5-6, 2008, Pages 211-229

  Li, Xiaodong ^a,c   Nott, Stephanie L ^a   huang, Yanfang ^a   Hilf, Russell ^a   Bambara, Robert A ^a   Qiu, Xing ^a   Yakovlev, Andrei ^a   Welle, Stephen ^a   Muyan, Mesut ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b HD Dimension Corporation ^*  (United States)

^c HD Dimension Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; ESTRADIOL; ESTROGEN RECEPTOR BETA; LIPOCORTIN 5; DNA;

ADENOVIRUS; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NICK END LABELING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; WOUND HEALING; BIOLOGICAL MODEL; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR BETA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE; PROTEIN BINDING; RESPONSE ELEMENTS;

EID: 45549098114     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-07-0156     Document Type: Article

References (80)

1. Aho S, Rouda S, Kennedy SH, Qin H & Tan EM 1997 Regulation of human interstitial collagenase (matrix metalloproteinase-1) promoter activity by fibroblast growth factor. European Journal of Biochemistry 247 503-510.
2. Andreasen PA, Kjoller L, Christensen L & Duffy MJ 1997 The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal Cancer 72 1-22.
3. Archer TK, Lefebvre P, Wolford RG & Hager GL 1992 Transcription factor loading on the MMTV promoter: a bimodal mechanism for promoter activation. Science 255 1573-1576.
4. Bjornstrom L & Sjoberg M 2002 Mutations in the estrogen receptor DNA-binding domain discriminate between the classical mechanism of action and cross-talk with Stat5b and activating protein 1 (AP-1). Journal of Biological Chemistry 277 48479-48483.
5. Bjornstrom L & Sjoberg M 2004 Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nuclear Receptor 2 3.
6. Bjornstrom L, Kilic E, Norman M, Parker MG & Sjoberg M 2001 Cross-talk between Stat5b and estrogen receptor-α and -β in mammary epithelial cells. Journal of Molecular Endocrinology 27 93-106.
7. Buttice G, Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen M & Stehelin D 1996 Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13 2297-2306.
8. Cheung E, Acevedo ML, Cole PA & Kraus WL 2005 Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1. PNAS 102 559-564.
9. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H et al. 2005 Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Research 33 e175.
10. Dai M, Wang P, Jakupovic E, Watson SJ & Meng F 2007 Web-Based GeneChip Analysis System for Large-Scale Collaborative Projects. Bioinformatics 23 2185-2187.
11. Deroo BJ & Korach KS 2006 Estrogen receptors and human disease. Journal of Clinical Investigation 116 561-570.
12. Duan R, Porter W & Safe S 1998 Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139 1981-1990.
13. Duffy MJ, Maguire TM, Hill A, McDermott E & O'Higgins N 2000 Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Research 2 252-257.
14. Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S & Lapointe K 2007 The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. British Journal of Cancer 96 646-653.
15. Fowler AM, Solodin N, Preisler-Mashek MT, Zhang P, Lee AV & Alarid ET 2004 Increases in estrogen receptor-α concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB Journal 18 81-93.
16. Fowler AM, Solodin NM, Valley CC & Alarid ET 2006 Altered target gene regulation controlled by estrogen receptor-α concentration. Molecular Endocrinology 20 291-301.
17. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR & Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562-4574.
18. Garcia M, Derocq D, Freiss G & Rochefort H 1992 Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. PNAS 89 11538-11542.
19. Garcia M, Derocq D, Platet N, Bonnet S, Brouillet JP, Touitou I & Rochefort H 1997 Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor. Journal of Steroid Biochemistry and Molecular Biology 61 11-17.
20. Gautier L, Moller M, Friis-Hansen L & Knudsen S 2004 Alternative mapping of probes to genes for Affymetrix chips. BMC Bioinformatics 5 111.
21. Glidewell-Kenney C, Weiss J, Lee EJ, Pillai S, Ishikawa T, Ariazi EA & Jameson JL 2005 ERE-independent ERa target genes differentially expressed in human breast tumors. Molecular and Cellular Endocrinology 245 53-59.
22. Gorczyca W, Melamed MR & Darzynkiewicz Z 1998 Analysis of apoptosis by flow cytometry. Methods in Molecular Biology 91 217-238.
23. Gotte M & Yip GW 2006 Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Research 66 10233-10237.
24. Green S, Kumar V, Theulaz I, Wahli W & Chambon P 1988 The N-terminal DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO Journal 7 3037-3044.
25. Hall JM & McDonnell DP 1999 The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 5566-5578.
26. Hall JM, Couse JF & Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. Journal of Biological Chemistry 276 36869-36872.
27. Harbig J, Sprinkle R & Enkemann SA 2005 A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Research 33 e31.
28. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA & Katzenellenbogen BS 2003 Activities of estrogen receptor α- and β-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Molecular and Cellular Endocrinology 206 13-22.
29. Huang J, Li X, Yi P, Hilf R, Bambara RA & Muyan M 2004 Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes. Molecular and Cellular Endocrinology 218 65-78.
30. Huang J, Li X, Hilf R, Bambara RA & Muyan M 2005a Molecular basis of therapeutic strategies for breast cancer. Current Drug Targets. Immune, Endocrine and Metabolic Disorders 5 379-396.
31. Huang J, Li X, Maguire CA, Hilf K, Bambara RA & Muyan M 2005b Binding of estrogen receptor β to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Molecular Endocrinology 19 2696-2712.
32. Ito Y, Takeda T, Higashiyama S, Noguchi S & Matsuura N 2001 Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Research and Treatment 67 81-85.
33. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD & Jameson JL 2001 Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. Journal of Biological Chemistry 276 13615-13621.
34. Jiang SY & Jordan VC 1992 Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. Journal of National Cancer Institute 84 580-591.
35. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR & Leitman DC 2004 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Molecular Biology of the Cell 15 1262-1272.
36. Klebanov L, Gordon A, Xiao Y, Land H & Yakovlev A 2006 A permutation test motivated by microarray data analysis. Comparative Statistics and Data Analysis 50 3619-3628.
37. Korsmeyer SJ 1999 Programmed cell death and the regulation of homeostasis. Harvey Lectures 95 21-41.
38. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311-317.
39. Laganiere J, Deblois G & Giguere V 2005 Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor α1 gene in breast cancer cells. Molecular Endocrinology 19 1584-1592.
40. Lazennec G & Katzenellenbogen BS 1999 Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells. Molecular and Cellular Endocrinology 149 93-105.
41. Lazennec G, Bresson D, Lucas A, Chauveau C & Vignon F 2001 ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 4120-4130.
42. Lee HL & Archer TK 1994 Nucleosome-mediated disruption of transcription factor-chromatin initiation complexes at the mouse mammary tumor virus long terminal repeat in vivo. Molecular Cell Biology 14 32-41.
43. Li X, Huang J, Yi P, Bambara RA, Hilf R & Muyan M 2004 Single-chain estrogen receptors (ERs) reveal that the ERα/β heterodimer emulates functions of the ERα rumor in genomic estrogen signaling pathways. Molecular Cell Biology 24 7681-7694.
44. Li Y, Li L, Brown TJ & Heldin P 2007 Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. International Journal of Cancer 120 2557-2567.
45. Licznar A, Caporali S, Lucas A, Weisz A, Vignon F & Lazennec G 2003 Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. FEBS Letters 553 445-450.
46. T Method. Methods 25 402-408.
47. Luisi BF, Schwabe JW & Freedman LP 1994 The steroid/nuclear receptors: from three-dimensional structure to complex function. Vitamins and Hormone 49 1-47.
48. McKenna NJ, Lanz RB & O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321-344.
49. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M & Gannon F 2003 Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 751-763.
50. Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, Kimber I & Orphanides G 2005 Anti-proliferative effect of estrogen in breast cancer cells that re-express ERα is mediated by aberrant regulation of cell cycle genes. Journal of Molecular Endocrinology 34 535-551.
51. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S & Spelsberg TC 2005 Estrogen receptor α and β heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Molecular Endocrinology 19 1555-1568.
52. Monslow J, Williams JD, Fraser DJ, Michael DR, Foka P, Kift-Morgan AP, Luo DD, Fielding CA, Craig KJ, Topley N et al. 2006 Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. Journal of Biological Chemistry 281 18043-18050.
53. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicitv assays. Journal of Immunological Methods 65 55-63.
54. Mosselman S, Polman J & Dijkema R 1996 ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 392 49-53.
55. Muyan M, Yi P, Sathya G, Willmert LJ, Driscoll MD, Hilf R & Bambara RA 2001 Fusion estrogen receptor proteins: toward the development of receptor- based agonists and antagonists. Molecular and Cellular Endocrinology 182 249-263.
56. Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K & Emi M 2005 Identification of RAI3 as a therapeutic target for breast cancer. Endocrine-Related Cancer 12 65-73.
57. Nettles KW, Bruning JB, Gil G, O'Neill EE, Nowak J, Guo Y, Kim Y, DeSombre ER, Dilis R, Hanson RN et al. 2007 Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Reports 8 563-568.
58. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson JA 2001 Mechanisms of estrogen action. Physiological Reviews 81 1535-1565.
59. Nunez AM, Berry M, Imler JL & Chambon P 1989 The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO Journal 8 823-829.
60. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277 1508-1510.
61. Parker MG 1998 Transcriptional activation by oestrogen receptors. Biochemical Society Symposium 63 45-50.
62. Pasonen-Seppanen S, Karvinen S, Torronen K, Hyttinen JM, Jokela T, Lammi MJ, Tammi MI & Tammi R 2003 EGF upregulates, whereas TGF-β downregulates, the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. Journal of Investigative Dermatology 120 1038-1044.
63. Pennie WD, Hager GL & Smith CL 1995 Nucleoprotein structure influences the response of the mouse mammary tumor virus promoter to activation of the cyclic AMP signalling pathway. Molecular Cell Biology 15 2125-2134.
64. Rishi AK, Shao ZM, Baumann RG, Li XS, Sheikh MS, Kimura S, Bashirelahi N & Fontana JA 1995 Estradiol regulation of the human retinoic acid receptor α gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. Cancer Research 55 4999-5006.
65. Saavalainen K, Pasonen-Seppanen S, Dunlop TW, Tammi R, Tammi MI & Carlberg C 2005 The human hyaluronan synthase 2 gene is a primary retinoic acid and epidermal growth factor responding gene. Journal of Biological Chemistry 280 14636-14644.
66. Safe S 2001 Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitamins and Hormone 62 231-252.
67. Schultz JR, Petz LN & Nardulli AM 2003 Estrogen receptor α and Sp1 regulate progesterone receptor gene expression. Molecular and Cellular Endocrinology 201 165-175.
68. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR & Katzenellenbogen BS 2004 Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145 3473-3486.
69. Sun G, Porter W & Safe S 1998 Estrogen-induced retinoic acid receptor α 1 gene expression: role of estrogen receptor-Sp1 complex. Molecular Endocrinology 12 882-890.
70. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW & Brown TJ 2005 Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Research 65 6139-6150.
71. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y & Kamada T 1994 Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. Journal of Biological Chemistry 269 16433-16442.
72. Vyhlidal C, Samudio I, Kladde MP & Safe S 2000 Transcriptional activation of transforming growth factor α by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. Journal of Molecular Endocrinology 24 329-338.
73. Watkins G, Douglas-Jones A, Mansel RE & Jiang WG 2005 Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. International Seminars in Surgical Oncology 2 23.
74. Webb P, Lopez GN, Uht RM & Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 443-456.
75. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S et al. 1999 The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Molecular Endocrinolgy 13 1672-1685.
76. Westfall PH & Young S 1993. Resampling-Based Multiple Testing, New York: Wiley.
77. Wyatt CA, Geoghegan JC & Brinckerhoff CE 2005 Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Research 65 11101-11108.
78. Yi P, Bhagat S, Hilf R, Bambara RA & Muyan M 2002a Differences in the abilities of estrogen receptors to integrate activation functions are critical for subtype-specific transcriptional responses. Molecular Endocrinology 16 1810-1827.
79. Yi P, Driscoll MD, Huang J, Bhagat S, Hilf R, Bambara RA & Muyan M 2002b The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ERα and ERβ. Molecular Endocrinology 16 674-693.
80. Zajchowski DA, Sager R & Webster L 1993 Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Research 53 5004-5011.